Related Experiment Video

Updated: Jan 4, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.3K

PADI3 plays an antitumor role via the Hsp90/CKS1 pathway in colon cancer

Zhengbin Chai1, Li Wang2, Yabing Zheng3

  • 1Department of Laboratory Medicine, Jinan Infectious Disease Hospital, Jingshi Road 22029, Jinan, 250021 Shandong People's Republic of China.

Cancer Cell International
|November 12, 2019
PubMed
Abstract

Insights

PADI3 inhibits colon cancer growth by reducing Hsp90 and CKS1 expression. This study clarifies the upstream regulation of CKS1, offering new insights into colon cancer progression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • CKS1 is highly expressed in colon cancer and drives proliferation.
  • The upstream regulation of CKS1 in colon cancer remains largely unknown.
  • PADI3 has known anti-tumor roles by suppressing cell proliferation.

Purpose of the Study:

  • Investigate the regulatory mechanism of PADI3 and CKS1 in colon cancer.
  • Determine the relationship between PADI3 and CKS1 expression in colon cancer.
  • Elucidate how PADI3 influences CKS1-driven cancer cell proliferation.

Main Methods:

  • Gene expression analysis (Western blot, real-time PCR).
  • Cell proliferation and colony formation assays (CCK-8, colony formation assays).
  • In vivo tumor growth studies in BALB/c nude mice.

Main Results:

  • CKS1 overexpression promotes colon cancer cell proliferation and tumor growth.
  • PADI3 and CKS1 expression are negatively correlated in clinical colon cancer samples.
  • PADI3 downregulates CKS1 expression, an effect dependent on Hsp90.

Conclusions:

  • PADI3 exerts antitumor activity by inhibiting Hsp90 and CKS1.
  • Hsp90 is crucial for PADI3-mediated suppression of CKS1 expression.
  • Understanding this PADI3-Hsp90-CKS1 axis offers therapeutic targets for colon cancer.
Keywords:
CKS1Cell proliferationColon cancerHsp90PADI3

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.2K
Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells11:06

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells

Published on: May 20, 2015

29.6K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
11.7K